Jane Skelton, MD
Medical Oncology · Delray Beach, FLNPI 1225086051
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Novartis at 53.1% of the total. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 130 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Johnson & Johnson$391
- Seagen Inc.$212
- AstraZeneca$197
- Puma Biotechnology, Inc.$174
- Daiichi Sankyo Inc.$145
- plus $851 from 22 others
Across 9 payments — averaging $2126.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$18K
- Fujirebio Diagnostics, Incorporated$1K
What the payments were for
- Food & beverage$1,93246%
- Education$832%
- Other$2,18152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $2,227 |
| Johnson & Johnson(2 entities) | 29 | $391 |
| Seagen Inc. | 6 | $212 |
| AstraZeneca(2 entities) | 9 | $197 |
| Puma Biotechnology, Inc. | 4 | $174 |
| Daiichi Sankyo Inc. | 2 | $145 |
| Lilly USA, LLC | 5 | $123 |
| E.r. Squibb & Sons, L.L.C. | 6 | $80 |
| Genentech USA, Inc. | 5 | $77 |
| Merck | 6 | $76 |
| Sanofi | 4 | $62 |
| Gilead | 3 | $54 |
| Bristol Myers Squibb | 2 | $37 |
| Incyte Corporation | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Dova Pharmaceuticals | 2 | $28 |
| Tempus AI, Inc | 1 | $27 |
| Amgen | 2 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $23 |
| Immunogen, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,197 in reported general payments places this provider in the 35th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 171 | $4,464 |
| Exemestane | 12 | $2,467 |
| Anastrozole | 93 | $2,086 |
| Tamoxifen Citrate | 62 | $1,988 |
| Alendronate Sodium | 19 | $243 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Delray Beach
- Warren BrennerDelray Beach$99K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.